| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
NMO Spectrum Evaluation (AQP4 with Reflex to MOG), CSF
Test Code38313
CPT Codes
86052
Includes
If the Aquaporin 4 Antibody, CSF is positive, then Aquaporin 4 Antibody, Titer, CSF will be performed at an additional charge (CPT code: 86052).
If the Aquaporin 4 Antibody, CSF is negative, then MOG Antibody, CBA will be performed at an additional charge (CPT code: 86362).
If the MOG Antibody, CBA, CSF is positive, then MOG Antibody, Titer, CSF will be performed at an additional charge (CPT code: 86362).
If the Aquaporin 4 Antibody, CSF is negative, then MOG Antibody, CBA will be performed at an additional charge (CPT code: 86362).
If the MOG Antibody, CBA, CSF is positive, then MOG Antibody, Titer, CSF will be performed at an additional charge (CPT code: 86362).
Preferred Specimen
2 mL CSF collected in a sterile plastic screw-cap vial
Minimum Volume
1 mL
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 21 days
Refrigerated: 14 days
Frozen: 21 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Visible particulate matter
Methodology
Cell-based Immunofluorescence Assay
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Night Sets up 2 days a week.
Report Available
Reports in 7 to 10 days.
Clinical Significance
NMO (neuromyelitis optica, Devic disease) is an immune- mediated chronic inflammatory disease that predominantly affects the optic nerve and spinal cord and presents with optic neuritis (ON) and myelitis. Limited forms of this disease, such as isolated ON, brainstem encephalitis and longitudinal extensive transverses myelitis (LETM), have been referred to as NMO spectrum disorders (NMOSD). NMO was originally thought to be a variant of multiple sclerosis but is now recognized as a distinct disease. The presence of serum antibodies against aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein (MOG-IgG) is associated with NMO and NMOSD.
